ILEU20019/20190014/ Kristen O'Dwyer
Basic Study Information
Purpose:Location: University of Rochester Cancer Center
The study aims to determine the safety and feasibility of complete outpatient blinatumomab
administration for subjects with minimal/measurable residual disease (MRD) of B-precursor
Acute Lymphoblastic Leukemia (ALL).
Lead Researcher (Principal Investigator)
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search